Crinetics Pharmaceuticals, Inc. (CRNX) announced pricing of upsized underwritten public offering of 10 million common shares at $50.00 per share. The offering is expected to close on or about October 10, 2024.
Crinetics also granted the underwriters a 30-day option to purchase up to an additional 1.5 million common shares. The company expects offering gross proceeds, before expenses, to be $500.0 million.
Crinetics intends to use offering net proceeds, together with cash, cash equivalents and investment securities, to fund research and development, other research programs, pre-commercialization activities and other general corporate purposes.
For comments and feedback contact: editorial@rttnews.com
Business News
June 12, 2026 17:14 ET Major central bank action was the focus this week in economic news. The European Central Bank became the first major central bank to move in response to the rising inflationary pressures in the backdrop of the conflict in the Middle East. In North America, the U.S. inflation and trade data as well as Canada’s central bank decision gained attention. The Chinese trade data was the main news in Asia.